Compliance Question of the Week – General

When are the code series 0537T-0540T reported?

Are codes 96372 and 96373 affected by the determination of the primary or secondary intent of the encounter?

How is tocilizumab for COVID-19 reported? Can we report it in an outpatient setting?

Is care on the same date of service that is not directly related to the service of administration of the CAR-T cells separately reportable?

Can we separately report codes 96360 and 96361 for CAR-T?

For CAR-T cell administration, can we report lymphodepleting (LD) chemotherapy separately if it is administered prior to the day that cell therapy is administered?

Can we charge separately for supportive medicated injections/infusions given at the time of the cell therapy?

Can you tell me more about the guidelines for how CART-T infusion is administered and performed?

How do we report CAR-T drug administration in the hospital outpatient setting?

Do we need to report start and stop times in the medical record when reporting 0540T?

For billing chemotherapy infusions, what determines the selection of the primary CPT code?

When it comes to reporting for intraperitoneal chemotherapy, how do we code for IV push of an anti-emetic agent when it is added to the treatment plan?